Skip to main navigation

About
- Team
- Contact
Research & Development
Pipeline
- RMC-4630
- Mutant RAS
- SOS1
- RMC-5552
Investors
Careers

Press Releases

Press Releases

Year

January 11, 2022

Revolution Medicines Reports Progress Across Pipeline of Targeted Therapeutics for RAS-Addicted Cancers in Presentation at 40th Annual J.P. Morgan Healthcare Conference

January 4, 2022

Revolution Medicines to Provide R&D Update, Including Expansion of Development-Stage RAS(ON) Inhibitor Pipeline, During Presentation at 40th Annual J.P. Morgan Healthcare Conference

November 24, 2021

Revolution Medicines to Participate in 4th Annual Evercore ISI HealthCONx Conference

November 10, 2021

Revolution Medicines Reports Third Quarter Financial Results and Update on Corporate Progress

November 8, 2021

Revolution Medicines to Participate in Stifel 2021 Virtual Healthcare Conference

November 3, 2021

Revolution Medicines to Report Financial Results for Third Quarter 2021 After Market Close on November 10, 2021

September 30, 2021

Revolution Medicines to Present New Preclinical Data from RAS(ON) Inhibitor Programs at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

September 15, 2021

Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit

September 7, 2021

Revolution Medicines to Present at H.C. Wainwright 23rd Annual Global Investment Conference

August 11, 2021

Revolution Medicines Reports Second Quarter Financial Results and Update on Corporate Progress

Pagination

Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Next page
Last page

Displaying 1 - 10 of 72

Email Alerts

RSS Feeds

Print Page

Contact IR

© 2022 Revolution Medicines, Inc. | 700 Saginaw Drive | Redwood City, CA 94063
CCPA Notice | Privacy Policy

Search Investor Relations